| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | MS4A1 | Synonyms | B1, Bp35, CD20, CVID5, FMC7, LEU-16, S7 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | |
| Description | membrane spanning 4-domains A1 | ||||
| GTO ID | GTC2659 |
| Trial ID | NCT04844866 |
| Disease | Diffuse Large B-Cell Lymphoma |
| Altered gene | CD20|CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | MB-CAR-T2019.1 |
| Generation | 2nd |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients |
| Year | 2021 |
| Country | Austria |
| Company sponsor | Miltenyi Biomedicine GmbH |
| Other ID(s) | M-2020-371 |
| Cohort 1 | |||||||||||
|
|||||||||||